
## IN THE CLAIMS

1. (Original) A compound selected from Formula I-XV,



or a pharmaceutically acceptable salt thereof, wherein

X is N or CR14;

W is S, O, or NR<sup>15</sup>;

Y is N or CR<sup>3</sup>;

E, F, and G are each, independently, CR3 or N;

I and J are each, independently,

C=O, S, O, CR<sup>3</sup>R<sup>16</sup> or NR<sup>15</sup> when single bonded to both adjacent ring atoms, or N, or CR<sup>3</sup> when double bonded to an adjacent ring atom;

K is

N or CR<sup>3</sup> when double bonded to L or J, or

O, S, C=O, CR<sup>3</sup>R<sup>16</sup>, or NR<sup>15</sup> when single bonded to both adjacent ring atoms, or N or CR<sup>3</sup> when double bonded to an adjacent ring atom;

L is

N or CR<sup>16</sup> when single bonded to all atoms to which it is attached, or C (carbon) when double bonded to K;

the 6- or 7-membered ring that contains I, J, K, and L may contain from 1 to 3 double bonds, from 0 to 2 heteroatoms, and from 0 to 2 C=O groups, wherein the carbon atom of such groups are part of the ring and the oxygen atom is a substituent on the ring;

Q is O or NR<sup>15</sup>;

 $R^1$  is selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $(C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkynyl, cyano, halo,  $C_1$ - $C_6$  haloalkyl,  $OR^7$ ,  $C_1$ - $C_6$  alkyl- $OR^7$ ;  $C_1$ - $C_6$  cyanoalkyl,  $NR^8R^9$ ,  $C_1$ - $C_6$  alkyl- $NR^8R^9$ ;

R<sup>2</sup> is H,

 $C_1$ - $C_6$  alkyl which optionally forms a  $C_3$ - $C_6$  aminocarbocycle or a  $C_2$ - $C_5$  aminoheterocycle with A or B, each optionally substituted at each occurrence with  $R^7$ ,  $C_3$ - $C_{10}$  cycloalkyl, or

 $(C_3-C_{10} \text{ cycloalkyl}) C_1-C_6 \text{ alkyl};$ 

or R<sup>2</sup> and R<sup>6</sup> jointly form with the 2 nitrogen atoms to which they are bound a C<sub>2</sub>-C<sub>5</sub> aminoheterocycle optionally substituted at each position with R<sup>7</sup>;

- A is  $(CH_2)_m$  where m is 1,2 or 3 and is optionally mono- or di-substituted on each occurrence with  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $(C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkynyl, cyano, halo,  $C_1$ - $C_6$  haloalkyl,  $OR^7$ ,  $C_1$ - $C_6$  alkyl- $OR^7$ ;  $C_1$ - $C_6$  cyanoalkyl,  $OR^8R^9$ ,  $C_1$ - $C_6$  alkyl- $OR^8R^9$ , or
- A and B jointly form a C<sub>3</sub>-C<sub>6</sub> carbocycle, optionally substituted at each position with R<sup>7</sup> or,
- A and  $R^2$  jointly form a  $C_3$ - $C_6$  aminocarbocycle or a  $C_2$ - $C_5$  aminoheterocycle optionally substituted at each position with  $R^7$ ;
- B is (CH<sub>2</sub>)<sub>n</sub> where n is 1,2 or 3 and is optionally mono- or di-substituted on each carbon atom with C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, cyano, halo, C<sub>1</sub>-C<sub>6</sub> haloalkyl, OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>; C<sub>1</sub>-C<sub>6</sub> cyanoalkyl, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, or
- B and R<sup>2</sup> jointly form a C<sub>3</sub>-C<sub>6</sub> aminocarbocycle or a C<sub>2</sub>-C<sub>5</sub> aminoheterocycle optionally substituted at each position with R<sup>7</sup>;

- R³ and R¹6 are independently selected at each occurrence from H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, (C₃-C₁₀ cycloalkyl) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cyano, halogen, C₁-C₆ haloalkyl, OR¹, C₁-C₆ alkyl-OR¹, C₁-C₆ cyanoalkyl, NR¹R², C₁-C₆ alkyl-NR¹R²,
- R<sup>4</sup> is selected from aryl or heteroaryl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, trifluromethylsulfonyl, OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-COOR<sup>7</sup>, CN, C<sub>1</sub>-C<sub>6</sub> alkyl-CN, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the heterocyclic core is substituted;

## R<sup>5</sup> is selected from:

- C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from halo, C<sub>1</sub>-C<sub>2</sub> haloalkyl, OR<sup>7</sup>, cyano, NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, NR<sup>11</sup>COR<sup>12</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>7</sup>;
- C<sub>1</sub>-C<sub>6</sub> arylalkyl, C<sub>1</sub>-C<sub>6</sub> heteroarylalkyl, C<sub>5</sub>-C<sub>8</sub> arylcycloalkyl, or C<sub>5</sub>-C<sub>8</sub> heteroarylcycloalkyl, where aryl is phenyl or naphthyl, and heteroaryl is 2-,3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, triazinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5-oxazolyl, isoxazolyl, indolyl, pyrazolyl, quinolyl, isoquinolyl, 2-, 4-, or 5-thiazolyl, benzothiadiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4-triazolyl, 2-triazinyl, 2-pyrazinyl, 2-, or 3-furanyl, 2-, or 3-thienyl, 2-, or 3-benzothienyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally

substituted with 1 to 5 substituents independently selected at each occurrence from  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl, halogen,  $C_1$ - $C_6$  haloalkyl, trifluromethylsulfonyl,  $OR^7$ ,  $NR^8R^9$ ,  $C_1$ - $C_6$  alkyl- $OR^7$ ,  $C_1$ - $C_6$  alkyl- $NR^8R^9$ ,  $CONR^8R^9$ ,  $COOR^7$ , CN,  $SO_2NR^8R^9$ ,  $SO_2R^7$ , aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a  $C_3$ - $C_{10}$  cycloalkyl ring, a  $C_3$ - $C_{10}$  cycloalkenyl ring or a heterocycloalkyl ring;

 $C_3$ - $C_{10}$  cycloalkyl, ( $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$ alkynyl, each of which is optionally with 1 to 6 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, with the proviso that when two OR<sup>7</sup> or NR<sup>8</sup>R<sup>9</sup> substituents are geminally located on the same carbon R<sup>7</sup> is not H and they can form together a C<sub>2</sub>-C<sub>4</sub> ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, CN, oxo, hydroximino, C<sub>1</sub>-C<sub>6</sub> alkoximino, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $(C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, trifluromethylsulfonyl, OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, CN, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C<sub>3</sub>-C<sub>10</sub> cycloalkyl ring, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl ring or a heterocycloalkyl ring;

aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at

each occurrence from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, trifluromethylsulfonyl, OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, CN, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C<sub>3</sub>-C<sub>10</sub> cycloalkyl ring, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl ring or a heterocycloalkyl ring;

or

- 3- or 4-piperidinyl, 3-pyrrolidinyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydropyranyl, 3- or 4-(1,1-dioxo) tetrahydrothiopyranyl, 1-azabicyclo[4.4.0]decyl, 8-azabicyclo[3.2.1]octanyl, norbornyl, quinuclidinyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from R<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>;
- R<sup>6</sup> is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> arylalkyl, C<sub>1</sub>-C<sub>6</sub> heteroarylalkyl where aryl or heteroaryl are optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, OR<sup>13</sup>, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>13</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>7</sup>, CN, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>7</sup>, or R<sup>6</sup> and R<sup>2</sup>, as mentioned above, jointly form, with the 2 nitrogen atoms to which they are bound, a C<sub>2</sub>-C<sub>5</sub> aminoheterocycle optionally substituted at each position with R<sup>7</sup>;

- R<sup>7</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, (C<sub>3</sub>-C<sub>10</sub> cycloalkyl) C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> haloalkyl, or heterocycloalkyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C<sub>1</sub>-C<sub>8</sub> alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub> arylalkyl or C<sub>1</sub>-C<sub>6</sub> heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, OR<sup>13</sup>, NR<sup>8</sup>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-OR<sup>13</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl-NR<sup>8</sup>R<sup>9</sup>, CONR<sup>8</sup>R<sup>9</sup>, COOR<sup>13</sup>, CN, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>13</sup>, with the proviso that when R<sup>7</sup> is SO<sub>2</sub>R<sup>13</sup>, R<sup>13</sup> cannot be H;
- $R^8$  and  $R^9$  are independently selected at each occurrence from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_6$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_6$  alkynyl, heterocycloalkyl,  $C_1$ - $C_8$  alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl,  $C_1$ - $C_6$  arylalkyl or  $C_1$ - $C_6$  heteroarylalkyl, or  $R^8$  and  $R^9$ , taken together, can form a  $C_3$ - $C_6$  aminocarbocycle or a  $C_2$ - $C_5$  aminoheterocycle each optionally substituted at each occurrence with  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_8$  haloalkyl, heterocycloalkyl,  $C_1$ - $C_8$  alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,  $C_1$ - $C_8$  alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl,  $C_1$ - $C_6$  arylalkyl or  $C_1$ - $C_6$  heteroarylalkyl;
- $R^{11}$  is selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, ( $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,
- $R^{12}$  is selected from H, aryl, heteroaryl,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $(C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl, optionally substituted with  $OR^7$ ,  $NR^8R^9$ [,  $C_3$ - $C_6$  aminocarbocycle, or  $C_2$ - $C_5$  aminoheterocycle;
- $R^{13}$  is independently selected at each occurrence from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, ( $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_1$ - $C_6$  haloalkyl, with the

proviso that for SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, SO<sub>2</sub>R<sup>13</sup>, R<sup>13</sup> cannot be H;

 $R^{14}$  is H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, ( $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl, halo, or CN; and

 $R^{15}$  is selected at each occurrence from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, ( $C_3$ - $C_{10}$  cycloalkyl)  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_2$ - $C_6$  alkyl- $OR^7$ ,  $C_2$ - $C_6$  cyanoalkyl,  $C_2$ - $C_6$  alkyl- $NR^8R^9$ .

Cancel Claims 2-75.

76. (original) A compound of claim 1 of formula XV and isomers thereof, stereoisomeric forms thereof, or mixture of stereoisomeric forms thereof, and pharmaceutically acceptable salt or prodrug forms thereof, selected from the group consisting of:

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclopentyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclohexyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is tetrahydropyranyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 3,4-dimethoxyphenethyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 1-pyrimidin-2-yl-piperidin-4-yl,

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,  $R^1$  is Me,  $R^3$  is Me,  $R^4$  is 2,4,6-trimethylphenyl,  $R^2$  is H, A is methylene, B is methylene,  $R^5$  is hydrogen,  $R^6$  is cyclopentyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,  $R^1$  is Me,  $R^3$  is Me,  $R^4$  is 2,4,6-trimethylphenyl,  $R^2$  is H, A is methylene, B is methylene,  $R^5$  is hydrogen,  $R^6$  is cyclohexyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,  $R^1$  is Me,  $R^3$  is Me,  $R^4$  is 2,4,6-trimethylphenyl,  $R^2$  is H, A is methylene, B is methylene,  $R^5$  is hydrogen,  $R^6$  is tetrahydropyranyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,  $R^1$  is Me,  $R^3$  is Me,  $R^4$  is 2,4,6-trimethylphenyl,  $R^2$  is H, A is methylene, B is methylene,  $R^5$  is hydrogen,  $R^6$  is 3,4-dimethoxyphenethyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,

R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,4,6-trimethylphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is

hydrogen, R<sup>6</sup> is 1-pyrimidin-2-yl-piperidin-4-yl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclopentyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclohexyl;

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is tetrahydropyranyl,

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 3,4-dimethoxyphenethyl,

a compound of formula XV wherein X is CH, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 1-pyrimidin-2-yl-piperidin-4-yl,

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,

R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is

methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclopentyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,

R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is

methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is cyclohexyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is tetrahydropyranyl,

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen, R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 3,4-dimethoxyphenethyl;

a compound of formula XV wherein X is N, Y is carbon, Q is oxygen,

R<sup>1</sup> is Me, R<sup>3</sup> is Me, R<sup>4</sup> is 2,6-dichloro-4-methoxyphenyl, R<sup>2</sup> is H, A is methylene, B is

methylene, R<sup>5</sup> is hydrogen, R<sup>6</sup> is 1-pyrimidin-2-yl-piperidin-4-yl.

Cancel Claims 77 - 91.

Respectfully submitted,

JOHN RICHÁRDS

LADAS & PARRY 26 WEST 61<sup>ST</sup> STREET NEW YORK, NEW YORK 10023

REG.NO.31053(212)708-1915